论文部分内容阅读
目的:观察中西医结合治疗晚期非小细胞肺癌(NSCLC)的临床疗效,以建立晚期非小细胞肺癌中西医结合临床优化治疗方案。方法:134例晚期NSCLC患者分为4组,正虚对照组(33例)、邪实对照组(33例)予顺铂(DDP)+多西紫杉醇(Doc)化疗;正虚观察组(34例)、邪实观察组(34例)在化疗基础上,正虚为主型予参芪扶正注射液和芪贞固本方;邪实为主型予苦参碱注射液和芩莲正积方。两周期后,比较两组患者治疗效果,观察1年,比较1年生存率。结果:与对照组相比,各观察组可明显提高肿瘤控制率、增加卡氏评分和体质量、降低症状积分和肿瘤标志物(CEA、CA19-9)、提高1年生存率、减轻消化道反应(P<0.05);扶正观察组与其对照组相比可明显增强患者免疫功能,减轻骨髓抑制(P<0.05)。结论:本研究所采用中西医结合治疗方案具有良好的治疗效果,能减毒增效,与单纯化疗相比有显著优势,值得临床广泛推广。
Objective: To observe the clinical efficacy of integrated traditional Chinese and western medicine in the treatment of advanced non-small cell lung cancer (NSCLC) to establish an optimal combination of traditional Chinese and western medicine for non-small cell lung cancer. Methods: One hundred and thirty-four patients with advanced NSCLC were divided into four groups: positive control group (33 cases), false positive control group (33 cases) and cisplatin (DDP) plus docetaxel chemotherapy Cases), evil real observation group (34 cases) on the basis of chemotherapy, the main virtual type to Shenqi Fuzheng injection and Qizhen Guben Fang; evil real type to matrine injection and Qin Lian is plot square. After two cycles, the two groups of patients were compared for therapeutic effect, observed for 1 year, compared with 1-year survival rate. Results: Compared with the control group, each observation group could significantly improve the tumor control rate, increase the Karnofsky’s score and body weight, reduce the symptom scores and tumor markers (CEA, CA19-9), improve the 1-year survival rate and reduce the digestive tract (P <0.05). Compared with the control group, Fuzheng observation group could significantly enhance the immune function and alleviate the bone marrow suppression (P <0.05). Conclusion: The combination of traditional Chinese and western medicine in this study has a good therapeutic effect, which can reduce the toxicity and increase the efficiency. Compared with the simple chemotherapy, it has significant advantages and worthy of widespread clinical promotion.